SUBSCRIBE
SUBSCRIBE
News   Drug Development

Exelixis, Inc. Says Quickly Filled Spots in Cancer Trial

January 11, 2008 | 
1 min read
SAN FRANCISCO, Jan 10 (Reuters) - Exelixis Inc (EXEL.O: Quote, Profile, Research) said it quickly attracted patients with non-small cell lung cancer for a trial of its experimental cancer drug XL647, Chief Executive George Scangos said on Thursday.
Clinical research Phase 2
Exelixis, Inc.
MORE ON THIS TOPIC
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie
illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
 · 
3 min read
 · 
Annalee Armstrong
3d human colon cross section with waste in the intestine isolated on green background. check colon health, constipation concept, 3d illustration render
Vaccines
Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?
February 17, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Scanner on blue human eye
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
February 17, 2026
 · 
2 min read
 · 
Tristan Manalac